STRO today
$9.64-$0.62 (-6.04%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourAscending Triangle
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns up above $49.40
Key levels
Resistance$11.80
Resistance$10.36
Support$9.36
Support$8.11
Latest news & SEC filings
ProductMerck ends development of MK-1484, an IL-2 agonist partnered with Sutro Biopharma
EarningsStrongPoint Posts Q3 2026 Results
ProductSutro Biopharma doses first patient in Phase 1 STRO-006 trial
All STRO news →About Sutro Biopharma
Sutro Biopharma is an oncology-focused biopharmaceutical company that designs antibody drug conjugates and other engineered protein therapies. It uses its own protein manufacturing and targeted conjugation technologies to build candidates aimed at solid tumors, led by STRO-004, which binds tissue factor. Earlier-stage programs include STRO-006 and a molecule carrying two distinct drug payloads. The company also runs research partnerships with larger drugmakers in cancer and infectious disease, and is based in the United States.
Based on the company's 10-K filed Mar 23, 2026.
Nasdaq · Healthcare
SUTRO BIOPHARMA, INC. (STRO)
What Is the Price Target for STRO?
SEPT Low Target
$41.00
SEPT Mid Target
$50.00
SEPT High Target
$60.00
Analyst Consensus
$50.00
Is STRO a Buy or Sell Right Now?
Thesis
- •Revenue growing 65.2% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for STRO.
Start Free Trial →Is STRO Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$50.00
30
Moat Score
NONE
2/9
Piotroski Score
-9.6
Altman Z-Score
What Is Smart Money Doing with STRO?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Gerber Hans-Peter | officer | Buy | 3,750 | - | Sep 18, 2026 |
| Gerber Hans-Peter | officer | Sale | 1,345 | $21K | Sep 18, 2026 |
| Chow Gregory K. | officer | Buy | 2,500 | - | Jun 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →STRO Growth Story
Revenue YoY
65.2%
3yr Revenue CAGR
14.8%
EPS Growth YoY
23.5%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for STRO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for STRO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:14:34 | $10.07 | 1,100 | $$11K | MIDPOINT |
| 21:00:29 | $10.17 | 1,152 | $$12K | SELL |
| 19:50:51 | $10.04 | 1,200 | $$12K | MIDPOINT |
| 17:58:32 | $10.27 | 3,300 | $$34K | MIDPOINT |
| 17:31:16 | $10.55 | 2,514 | $$27K | MIDPOINT |
5 dark pool trades shown · $$95K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for SUTRO BIOPHARMA, INC. (STRO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →STRO — frequently asked questions
What is STRO stock price today?
SUTRO BIOPHARMA, INC. (STRO) is at $9.64, down 6.04% (-$0.62) at the Nov 12, 2026 close.
Why is STRO stock moving today?
Latest STRO news — Nov 7, 2026: Merck ends development of MK-1484, an IL-2 agonist partnered with Sutro Biopharma · Oct 29, 2026: StrongPoint Posts Q3 2026 Results
What is the STRO price target?
The average analyst price target for STRO is $50.00, ranging from $41 to $60, based on 7 analysts.
What do analysts rate STRO?
Analyst ratings for STRO: 1 Buy, 9 Hold, 0 Sell — consensus Hold.
Did STRO beat earnings?
STRO last reported on Aug 12, 2026: EPS -$2.33 vs -$2.19 expected — a miss of 6.4%.
Does STRO pay a dividend?
STRO does not currently pay a dividend.
What are STRO support and resistance levels?
Support: $9.36, $8.11, $5.90. Resistance: $10.36, $11.80, $12.85.
What are insiders doing with STRO?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on STRO?
Nov 7, 2026: Merck ends development of MK-1484, an IL-2 agonist partnered with Sutro Biopharma · Oct 29, 2026: StrongPoint Posts Q3 2026 Results · Oct 22, 2026: Sutro Biopharma doses first patient in Phase 1 STRO-006 trial